Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company, announced participation in the 43rd Annual Cowen Healthcare Conference on March 8, 2023, at 9:10 a.m. ET in Boston. CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat.

A live webcast will be available in the Investors section of Nuvalent's website, with an archive accessible for 30 days post-event. Nuvalent focuses on developing targeted cancer therapies aimed at kinase targets, with ongoing programs for ROS1-positive and ALK-positive non-small cell lung cancer.

News Market Reaction – NUVL

-3.17%

-3.17% Session move

In the trading session that priced this news, NUVL declined 3.17%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 43^rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET in Boston. 

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-43rd-annual-cowen-healthcare-conference-301758736.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent participate in the Cowen Healthcare Conference?

Nuvalent will participate in the Cowen Healthcare Conference on March 8, 2023, at 9:10 a.m. ET.

Who from Nuvalent will be speaking at the conference?

CEO James Porter, Ph.D., and CFO Alexandra Balcom will be speaking at the conference.

Where can I watch the Nuvalent conference presentation?

You can watch the live webcast on the Investors section of Nuvalent's website.

What is Nuvalent's focus in biopharmaceuticals?

Nuvalent focuses on creating precisely targeted therapies for cancers, specifically developing treatments for kinase targets.

How long will the Nuvalent conference webcast be available?

The webcast will be archived for 30 days following the presentation.